Serdar Dursun

Academic Staff

12-127 Clinical Sciences Building

The aim of my research program is to investigate:

  • The neurobiological mechanisms and psychopharmacology of “refractory-treatment resistant” mental states using neurochemical, neuroimaging and neuropsychological techniques and clinical trials.
  • The clinical psychopharmacology of glutamate and nitric oxide in psychoses.
  • Molecular neuroscience of behavioural and neuroanatomical correlates of psychoses.

The objective is to maintain the research program across species. This translational neuro-scientific program will give us an indication of the validity of data across species and also a comparative assessment of pre-clinical vs. clinical research. Pre-clinical work helps us to understand the molecular basis of the mechanisms of action of psychotropic drugs and complements clinical data (from the molecule to the community).


  • Deakin B, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM (2008) Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 65: 154-164. 
  • Nasrallah HA, Dursun SM (2006) Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy. Editorial, J Psychopharmacol 20, suppl, 3-5. 
  • Haddad P, Dursun SM (2006) Selecting antipsychotics in schizophrenia: lessons from CATIE. J Psychopharmacol 20: 332-4. 
  • Devarajan S, Ali J, Dursun SM (2006) Quetiapine plus SSRI in treatment resistant depression; possible mechanisms. Psychopharmacol 18: 402-403.
  • Diaz P, Bhaskara S, Dursun SM, Deakin B (2005) Double-blind, placebo-controlled. Cross-over trial of clozapine plus glycine in refractory schizophrenia; Negative results. J Clin Psychopharmacol, 25: 277-278. 
  • Book: Psychiatric Drugs: A clinical guide to adverse syndromes, Oxford University Press, Editors: Dursun SM,Haddad PM and Deakin JFW (2004) ISBN 0-19-852748-9. 
  • Dursun SM, Haddad PM, Barnes TRE (2004) Extrapyramidal side-effects of psychotropic drugs. In: Psychiatric Drugs: A clinical guide to adverse syndromes, Oxford University Press, by P Haddad and JFW Deakin (2004) pp1-20. 
  • Denovan-Wright EM, Devarajan S, Dursun SM, Robertson HA (2002) Maintained improvement with minocycline of a patient with advanced Huntingdon’s disease. J Psychopharmacol, 16: 393-394.